Successful palliation with octreotide of a neuroendocrine syndrome from malignant melanoma

J Pain Symptom Manage. 2006 Aug;32(2):191-5. doi: 10.1016/j.jpainsymman.2006.02.014.

Abstract

We present a unique case of a neuroendocrine syndrome in a patient with Stage IV vaginal melanoma metastatic to the liver that was successfully palliated with octreotide. Similar to the carcinoid syndrome, the patient exhibited chronic diaphoresis, intermittent low-grade fevers, dizziness, nausea with vomiting, and hot flashes. The symptoms on admission of acute hypotension, acute exacerbation of abdominal pains, and intractable nausea with vomiting suggested a neuroendocrine crisis secondary to massive degranulation and hormone release. Consistent with our hypothesis, her plasma chromogranin A was found to be elevated. Octreotide was used successfully to palliate her symptoms. When the octreotide was stopped, all her symptoms returned. As the use of octreotide is gaining application in palliative care, this case highlights the effectiveness of its use in a select group of patients whose symptoms would be otherwise difficult to manage.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Pain / prevention & control*
  • Chest Pain / prevention & control*
  • Female
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Melanoma / drug therapy
  • Melanoma / secondary*
  • Middle Aged
  • Neuroendocrine Tumors / drug therapy
  • Neuroendocrine Tumors / secondary
  • Octreotide / therapeutic use*
  • Palliative Care / methods*
  • Syndrome
  • Treatment Outcome
  • Vaginal Neoplasms / drug therapy

Substances

  • Gastrointestinal Agents
  • Octreotide